Can I Take St. John's Wort with CJC-1295?

What CJC-1295 Is and How It Works

CJC-1295 (also called modified GRF 1-29 or mod-GRF) is a synthetic analog of growth hormone-releasing hormone (GHRH). It stimulates pulsatile release of growth hormone from anterior pituitary somatotroph cells by binding to the GHRH receptor. The "modified" designation refers to amino acid substitutions at positions 2, 8, 15, and 27 that improve resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) [1].

Pharmacokinetics of the Peptide

CJC-1295 has a half-life of approximately 30 minutes in its non-DAC (drug affinity complex) form. Clearance happens through proteolytic degradation by tissue and circulating peptidases, not through hepatic cytochrome P450 enzymes [2]. This distinction matters. Small-molecule drugs rely heavily on CYP-mediated metabolism, which makes them vulnerable to enzyme inducers like St. John's Wort. Peptides generally do not share that vulnerability.

Clinical Use Context

CJC-1295 is not FDA-approved. It is available through section 503A compounding pharmacies for off-label clinical use, typically prescribed for adult growth hormone deficiency, body composition optimization, or recovery support. Prescribers often combine it with other GH secretagogues such as ipamorelin in subcutaneous injection protocols [3].

What St. John's Wort Does to Drug Metabolism

St. John's Wort (Hypericum perforatum) is among the most clinically significant herbal enzyme inducers documented in pharmacology. A 2012 systematic review in Clinical Pharmacology & Therapeutics confirmed that hyperforin, its primary bioactive constituent, activates the pregnane X receptor (PXR), which upregulates transcription of CYP3A4, CYP2C9, CYP1A2, and the efflux transporter P-glycoprotein (P-gp) [4].

Scope of Enzyme Induction

The induction is not subtle. St. John's Wort reduces midazolam AUC (a CYP3A4 probe substrate) by 50% to 65% in healthy volunteers [5]. It lowers cyclosporine levels enough to cause organ transplant rejection. The FDA issued a 2000 advisory specifically warning about concomitant use with indinavir, cyclosporine, oral contraceptives, and other CYP3A4 substrates [6].

Timeline of Induction and Washout

Enzyme induction with St. John's Wort takes 7 to 14 days of consistent dosing (typically 300 mg three times daily, standardized to 0.3% hypericin) to reach full effect. After discontinuation, CYP3A4 activity returns to baseline over approximately 1 to 2 weeks, depending on individual variation and duration of prior use [4].

Direct Interaction Risk: Pharmacokinetic Analysis

The direct pharmacokinetic interaction between St. John's Wort and CJC-1295 is likely minimal. Here is why.

Peptide vs. Small-Molecule Metabolism

CJC-1295 is a 29-amino-acid peptide. Its primary clearance pathway is proteolytic cleavage by circulating and tissue-bound peptidases, including DPP-IV and neutral endopeptidases [2]. It does not undergo Phase I oxidative metabolism via CYP450 isoenzymes to any clinically meaningful degree. St. John's Wort's enzyme-inducing effects therefore do not directly accelerate CJC-1295 degradation.

No Published Interaction Data

No published clinical trial, case report, or pharmacovigilance signal describes a direct CJC-1295/St. John's Wort interaction. This absence is expected given the peptide's non-CYP clearance pathway. The Natural Medicines Comprehensive Database does not list CJC-1295 among drugs with documented St. John's Wort interactions [7].

The Low-Risk Classification Comes with a Caveat

Low direct risk does not mean zero clinical relevance. The concern shifts to indirect pharmacodynamic effects and the multi-drug context in which CJC-1295 is typically prescribed.

Indirect Risks That Actually Matter

The real clinical concern with combining St. John's Wort and CJC-1295 is not the peptide itself. It is everything else in the protocol.

Impact on Co-Administered Medications

CJC-1295 protocols frequently include other compounds: ipamorelin (another peptide, similarly low CYP risk), but also oral agents like anastrozole, metformin, or testosterone preparations. Anastrozole is a CYP3A4 substrate. St. John's Wort induction of CYP3A4 can reduce anastrozole plasma concentrations by a clinically significant margin, potentially undermining estrogen management in male patients on concurrent testosterone replacement therapy [8].

Metformin is not CYP-metabolized but is a substrate for organic cation transporters (OCTs). St. John's Wort effects on OCT transport are less well-characterized, though some in vitro data suggest modest inhibition of OCT1 [9].

Serotonergic Considerations

St. John's Wort inhibits reuptake of serotonin, norepinephrine, and dopamine. Growth hormone secretagogues, including CJC-1295, modulate hypothalamic signaling pathways that overlap with serotonergic circuits. A 2003 study in Neuroendocrinology demonstrated that serotonin receptor activation (particularly 5-HT1A and 5-HT2) modulates GHRH-stimulated GH release in humans [10]. Whether St. John's Wort's serotonergic activity meaningfully alters CJC-1295 efficacy remains unstudied, but the theoretical overlap exists.

Cortisol and HPA Axis Effects

St. John's Wort has documented effects on cortisol regulation. A randomized trial published in Neuropsychopharmacology (N=12 healthy volunteers) found that 600 mg of St. John's Wort extract significantly increased salivary cortisol levels during stress testing [11]. Elevated cortisol suppresses GH secretion through a well-established negative feedback mechanism at the hypothalamic level [12]. If St. John's Wort raises cortisol, it could blunt the GH-releasing effect of CJC-1295, reducing clinical benefit without producing an obvious "interaction" on a standard drug interaction screening tool.

Dose-Separation Strategy and Practical Guidance

If a patient and prescriber decide to continue both agents, a structured approach can minimize risk.

Timing Recommendations

Because the concern is not direct CYP-mediated metabolism of CJC-1295, traditional dose-separation windows (e.g., "take 2 hours apart") have limited pharmacokinetic rationale for the peptide itself. The more relevant timing consideration applies to any co-administered oral medications in the protocol.

For oral CYP3A4 substrates taken alongside CJC-1295 (such as anastrozole), consider:

• Taking the oral medication at a consistent time relative to St. John's Wort
• Monitoring drug levels or clinical effect 2 to 4 weeks after starting or stopping St. John's Wort
• Avoiding mid-cycle dosing changes to St. John's Wort, as fluctuating enzyme induction is harder to manage than steady-state induction

When to Stop St. John's Wort

The cleaner clinical decision is often to replace St. John's Wort with an alternative that does not induce CYP3A4. For mild-to-moderate depression (St. John's Wort's primary indication), options with no significant CYP3A4 induction include SAMe (S-adenosyl-L-methionine), which has meta-analytic support for efficacy comparable to tricyclic antidepressants [13], or direct consultation with a psychiatrist regarding low-dose SSRIs.

Monitoring Protocol When Using Both

Monitoring closes the gap between theoretical risk and actual patient outcomes.

Recommended Labs and Checkpoints

| Test | Timing | Purpose | |------|--------|---------| | IGF-1 | Baseline, then 6-8 weeks after adding or removing St. John's Wort | Assess whether GH axis output changes | | GH stimulation panel (if available) | Baseline and 8 weeks | Quantify pulsatile GH response to CJC-1295 | | Morning cortisol | Baseline and 4 weeks | Screen for cortisol elevation from St. John's Wort | | Liver function panel (AST/ALT) | Baseline and 8 weeks | Monitor hepatic enzyme induction burden | | Drug levels for co-administered CYP3A4 substrates | 2-4 weeks after any St. John's Wort dose change | Detect altered clearance |

Clinical Red Flags

Contact your prescriber immediately if you experience:

• Loss of previously stable CJC-1295 benefits (sleep quality, recovery, body composition) after starting St. John's Wort
• New insomnia, anxiety, or agitation (possible serotonergic excess)
• Unexpected changes in blood glucose if taking metformin or other diabetic agents concurrently

What to Do If You Are Already Taking Both

Many patients discover the interaction concern after they have been using both agents for weeks or months. Do not stop either abruptly without guidance.

Step-by-Step Approach

1. Disclose both agents to your prescriber. CJC-1295 is obtained through compounding pharmacies and St. John's Wort is over-the-counter, so neither may appear in a standard pharmacy interaction check.
2. Get baseline labs. Request IGF-1, morning cortisol, and a comprehensive metabolic panel. These establish whether your current regimen is producing expected results.
3. Evaluate necessity. Is St. John's Wort addressing a symptom that could be managed differently? Is CJC-1295 producing measurable benefit on labs and symptoms?
4. If discontinuing St. John's Wort, taper over 1 to 2 weeks rather than stopping abruptly. Abrupt cessation can cause rebound mood symptoms and unpredictable enzyme activity shifts during the washout period.
5. Recheck labs 6 to 8 weeks later to see whether IGF-1, cortisol, or other markers shift after St. John's Wort discontinuation.

Special Populations and Additional Cautions

Certain patients face amplified risk when combining these two agents.

Patients on Anticoagulants

St. John's Wort reduces warfarin levels through CYP2C9 and CYP3A4 induction, increasing clotting risk [4]. Any patient using warfarin alongside a CJC-1295 protocol should treat St. John's Wort as contraindicated, not merely cautionary. The INR destabilization risk alone justifies avoidance.

Patients on Hormonal Contraceptives

St. John's Wort reduces ethinylestradiol and norethindrone levels by inducing their CYP3A4-mediated metabolism, leading to breakthrough bleeding and contraceptive failure [14]. Women using hormonal contraception within a CJC-1295 protocol should not co-administer St. John's Wort.

Patients with Hepatic Impairment

Enzyme induction by St. John's Wort depends on functional hepatocyte mass. In patients with hepatic impairment, the induction effect is unpredictable, and baseline CYP3A4 activity may already be reduced. Adding an inducer to this scenario creates erratic drug levels for any co-administered oral medication [6].

The Regulatory Field for CJC-1295

CJC-1295 occupies a gray zone. It is not FDA-approved for any indication. It is available through 503A compounding pharmacies under physician prescription, but the FDA has periodically flagged GH secretagogues in enforcement actions against compounding facilities that market them for anti-aging without adequate clinical justification [15].

This regulatory status means interaction data will remain scarce. No pharmaceutical company is running Phase III trials on CJC-1295, so formal drug interaction studies (the kind the FDA requires for NDA submissions) do not exist and are unlikely to be conducted. Clinicians and patients must rely on pharmacologic first principles: peptide clearance pathways, known enzyme induction profiles, and clinical monitoring.